S-Oil inked an investment deal with modified sulfur maker Beomjun E&C to foray into new fields that can create synergy with its refining, lubricant, and petrochemical businesses.
The company also seeks mutual growth with small and medium-sized enterprises (SMEs).
Beomjun E&C uses byproduct sulfur generated from refining processes to produce hydraulic modified sulfur to be used in high-performance asphalt and concrete.
S-Oil had invested in four domestic startups. These were artificial intelligence-based industrial solutions firm OnePredict, flexible battery maker LIBEST, polyimide filmmaker IPITECH, and clean development mechanism firm Glory & Tech.
An S-Oil official revealed that they are considering making additional investments in firms related to smart factories, high-tech material, batteries, and carbon emission reduction.
The company intends to enter new markets like hydrogen, fuel cell, and recycling in its 2030 plan.


Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation
Zabka Shares Drop 10% as Seven & i Abandons Investment Plans
CXMT IPO Debut in Shanghai Puts $85.5 Billion Chipmaker in Spotlight
Barclays Q2 Profit Beats Forecasts as Investment Banking Strength Offsets Higher Costs
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake
Serica Energy to Acquire Pharos Energy for £145.7M, Sending PHARP Shares Soaring
Unilever Raises 2026 Sales Outlook After Strong Q2 Volume Growth
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook
Zhongji Innolight Raises $6.8 Billion in Hong Kong IPO as AI Demand Fuels Growth
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue
ASML, Applied Materials Slide as China DUV Chip Equipment Breakthrough Sparks Market Jitters
Seagate Stock Jumps as AI-Fueled Earnings Beat and Strong FY2027 Outlook Impress Investors
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline




